Heart Failure
Conference Coverage
Semaglutide win in HFpEF with obesity regardless of ejection fraction: STEP-HFpEF
It remains unknown, however, “whether the improvement in health status, functional status, and reduced inflammation” will translate to reduced...
Feature
The how and why of quad therapy in reduced-EF heart failure
“Yet, when we look at their actual implementation in clinical practice, we’ve seen this slow and variable uptake.”
From the Journals
History of heart transplant tied to worse pregnancy outcome
The findings demonstrate the importance of counseling HT patients at early gestational ages “to provide information about anticipated risks in...
From the Journals
Can a drug for overactive bladder disease prevent progression to heart failure?
Mirabegron had a neutral effect on LV mass and diastolic function for patients with pre-HF or mild HF.
Conference Coverage
SGLT2 inhibitors: No benefit or harm in hospitalized COVID-19
“I think the most important take-home message here is that the use of these medications appears to be safe even in really acutely ill hospitalized...
Conference Coverage
Recent leaps in heart failure therapy spur ESC guideline–focused update
The new document gives a boost to recommendations for HF with mildly reduced ejection fraction characterized by an LVEF > 40% to < 50%.
Commentary
Is AFib ablation the fifth pillar in heart failure care? CASTLE-HTx
Catheter ablation was superior to medical therapy alone in terms a composite endpoint of death from any cause or left...
Commentary
Heart failure guidelines update: What the ESC got right
Now we have very positive findings with the SGLT2 inhibitors, both dapagliflozin and ...
Latest News
Navigating chronic cough in primary care
“The most common associated comorbidities were heart failure and hypertension, but also conditions related to chronic pain, mood, and anxiety.”
Latest News
SGLT2i safety in acute heart failure confirmed by new data
Dapagliflozin appeared to improve diuresis and natriuresis while reducing the administered diuretic dose.
Latest News
Medicare announces 10 drugs targeted for price cuts in 2026
People on Medicare may in 2026 see prices drop for 10 medicines, including pricey diabetes, cancer, blood clot, and arthritis treatments.